Nabta Health is proud to announce its selection as the Best AI Startup and Best Overall Startup at the Accenture Innovation Cup as part of the GITEX Future Stars, where Nabta was selected from 750 different companies from across the Middle East and North Africa Region.

The awards come with fast-tracking for the Expo2020 Innovation Grant Program and an all-expenses-paid trip to Silicon Valley to meet with investors and potential partners courtesy of Accenture.

The Nabta team will continue to be present at Gitex Dubai this week and can be visited at stand G35 where we have been received with much interest from Gitex attendees as we continue to reimagine women's health through our updated Nabta Cycle application.

About Nabta Health – “Empowering Women Worldwide”

Nabta Health is the first dedicated platform for women’s health in the Middle East and North Africa. Its mission is to empower the 170 million women in the Arab world to more effectively manage their health and the health of their families.

Nabta provides a comprehensive set of digital health services to women, which mirror the health-related challenges and concerns that accompany every major event in their lives; from birth, through puberty, marriage, and pregnancy, to parenting, perimenopause and beyond.

Nabta’s digital platform brings much-needed transparency and access to women in the MENA region. It promises privacy and security to women trapped by a culture of shame and enables them to be proactive about their health.

More than simply providing privacy to women, however, Nabta uses proprietary technology to create a “Health 3.0” experience for women, featuring hybrid healthcare provision, personalized health insights from an artificially intelligent healthcare assistant, and blockchain-based Electronic Health Records (EHRs).

Nabta’s flagship product, Nabta Cycle, allows women to monitor all aspects of their reproductive health including the different phases of their menstrual cycle. Nabta Cycle is integrated with a real-time fertility monitor for 99% accurate ovulation prediction, detection of anovulatory cycles, and alerts regarding potential fertility issues. The fertility monitor is FDA-approved and CE certified.

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.